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	 A	series	of	novel	benzimidazole	derivatives	have	been	synthesized	by	the	condensation	of	o‐
phenylenediamine	with	4‐bromophenoxy	 acetic	 acid	and	product	 obtained	was	alkylated	 at
the	 benzimidazole	 ‐NH	 with	 different	 electrophilic	 reagents.	 Subsequent	 reactions	 of	 the
products	by	the	Suzuki	Coupling	between	benzimidazole	derivatives	and	phenylboronic	acid
derivatives	were	 accomplished.	All	 these	 compounds	were	 characterized	by	FT‐IR,	 1H	NMR,
MS	and	elemental	analysis.	These	compounds	were	screened	for	their	potential	antibacterial
and	antifungal	activities.	This	exhibited	some	promising	results	towards	testing	organism	in‐
vitro.	
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1.	Introduction	
	
The	 benzimidazole	 nucleus	 is	 a	 useful	 structure	 for	
research	 and	development	 of	 new	pharmaceutical	molecules.	
Benzimidazole	 are	 among	 the	 important	 heterocyclic	
compounds	found	in	several	natural	and	non‐natural	products	
such	 as	 Vitamin	 B12	 [1],	 marine	 alkaloid	 kealiiquinone	 [2],	
benzimidazole	nucleosides	[3,4]	etc.	Some	of	their	derivatives	
are	marketed	as	anti‐fungal	 [5],	anti‐helmintic	 [6,7]	and	anti‐
psychotic	[8,9]	drugs	and	other	derivatives	have	been	found	to	
possess	some	 interesting	bioactivities	such	as	anti‐tubercular	
[10],	 anti‐cancer	 [11,12],	 HIV‐inhibitors	 [13],	 anti‐hyperten‐
sive	 agent	 [14],	 anti‐inflammatory	 activity	 [15],	 anti‐allergic	
activity	[16],	anti‐diabetic	activity	[17],	anticonvulsant	activity	
[18],	DNA	inhibitory	activity	[19]	etc.	We	have	also	published	
some	series	of	biologically	active	benzimidazoles	 [20].	Owing	
to	 the	 immense	 biological	 importance	 of	 benzimidazole	
derivatives,	we	now	synthesized	some	novel	class	of	benzimi‐
dazole	 derivatives	 and	 their	 biological	 activity	 screening	
studies.		
	
	
2.	Experimental	
	
2.1.	Chemicals	
	
Phenylboronic	acid,	4‐ethyl	phenylboronic	acid,	palladium	
acetate,	 potassium	 fluoride	 and	 18‐crown‐6	 ether	 obtained	
from	 Aldrich.	 o‐Phenylenediamine,	 4‐bromophenoxy	 acetic	
acid,	 alkylating	 agents	 and	 sodium	 hydride	 were	 obtained	
from	 commercial	 suppliers.	 All	 the	 solvents	 used	 were	 of	
commercial	grade	only.	
	
2.2.	Instrumentations	
	
Melting	 points	 recorded	 on	 a	 MRVIS	 Series,	 Lab.	 India	
Instrument.	TLC	analysis	was	done	using	pre‐coated	silica	gel	
plates	 and	 visualization	 was	 done	 using	 iodine/UV	 lamp.	
Infrared	spectra	were	recorded	on	Perkin	Elmer	model	FT‐IR	
using	 the	 KBr	 disc.	 1H	 NMR	 spectra	 of	 the	 compounds	were	
recorded	 on	 BRUKER	Avance	 II	 400	MHz	NMR	 spectrometer	
with	CDCl3	as	solvent	unless	otherwise	mentioned.	Elemental	
analysis	was	carried	out	on	a	Perkin	Elmer	Series	II	Elemental	
Analyzer	2400.		
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Scheme	1
	
	
2.3.	Synthesis	
	
2.3.1.	Synthesis	of	2‐(4‐bromo‐phenoxymethyl)‐1H‐
benzimidaziole	by	condensation	of	o‐phenylenediamine	(1)	
(OPDA)	with	4‐bromophenoxy	acetic	acid	(2)	under	Philip’s	
condition	[21]		
		
To	 a	 solution	 of	 4‐bromophenoxy	 acetic	 acid	 (2)	 (10.8	 g,	
50	mmol)	and	4	N	HCl	(50	mL),	o‐phenylenediamine	(1)	(5.40	
g,	 50	 mmol)	 was	 added.	 The	 reaction	 mixture	 was	 heated	
slowly	 to	 reflux	 temperature	 for	 6	 hours	 (TLC	 monitoring).	
The	 reaction	mixture	 was	 then	 cooled	 to	 room	 temperature	
and	neutralized	with	10%	aq.	NaHCO3	till	the	neutral	pH.	The	
reaction	mixture	was	stirred	for	30	min	resulted	free	flowing	
suspension.	The	solid	separated	out	was	filtered,	washed	with	
water	 (3	×	30	mL)	 and	dried	under	 vacuum	 to	 afford	 an	off‐
white	solid.	The	crude	product	was	recrystallized	from	hot	aq.	
ethanol	 to	 obtain	 the	 pure	 white	 crystalline	 compound	 3	
(Scheme	1).	Yield:	13.5	g,	89	%.	M.p.:	260‐262	°C	(Lit.	[22]:	260	
°C).	
	
2.3.2.	Synthesis	of	compound	3	via	microwave	irradiation	
	
To	 a	 solution	 of	 4‐bromophenoxy	 acetic	 acid	 (2)	 (10.8	 g,	
50	mmol)	and	4	N	HCl	(50	mL),	o‐phenylenediamine	(1)	(5.40	
g,	50	mmol)	was	added.	The	reaction	mixture	was	irradiated	in	
a	microwave	oven	at	100	W	for	3	min	at	100	°C.	The	reaction	
mixture	was	then	cooled	to	room	temperature	and	neutralized	
with	 aq.	 NaHCO3	 (10%)	 till	 the	 neutral	 pH.	 The	 reaction	
mixture	 was	 stirred	 for	 30	 min	 resulted	 free	 flowing	
suspension.	The	solid	separated	out	was	filtered,	washed	with	
water	 (3	×	30	mL)	 and	dried	under	 vacuum	 to	 afford	 an	off‐
white	solid.	The	crude	product	was	recrystallized	from	hot	aq.	
ethanol	 to	 obtain	 the	 pure	 white	 crystalline	 compound	 3.	
Yield:	13.0	g,	87%.	M.p.:	260‐262	°C	(Lit.	[22]:	260	°C).	
	
2.3.3.	General	procedure	for	the	synthesis	of	N‐alkylated	
derivatives	of	2‐(4‐bromo‐phenoxymethyl)‐1H‐
benzimidaziole	(4a‐g)	[23]	
	
To	 a	 solution	 of	 2‐(4‐bromo‐phenoxymethyl)‐1H‐
benzimidazole	 (2	 mmol)	 (3)	 in	 dimethylformamide	 (10	mL)	
was	added	sodium	hydride	(60	%,	2.4	mmol)	lot	wise	at	0	°C.	
After	 completion	of	addition,	 the	 temperature	of	 the	 reaction	
mixture	was	slowly	raised	to	room	temperature	and	stirred	at	
this	 temperature	 for	 1	 h.	 The	 reaction	 mixture	 was	 again	
cooled	to	0	°C	and	the	respective	alkyl	halide	(2.4	mmol)	was	
added	 at	 0	 °C.	 The	 temperature	 of	 the	 reaction	mixture	was	
then	allowed	to	warm	to	room	temperature	and	stirred	for	2	h.	
After	completion	of	 the	 reaction,	 (TLC	monitoring)	water	 (50	
mL)	was	slowly	added	to	reaction	mixture	and	extracted	with	
ethyl	acetate	(2	×	25	mL).	The	organic	layer	was	washed	with	
water	 (2	 ×	 25	mL),	 brine	 and	 dried	 over	 anhydrous	 sodium	
sulfate	 and	 concentrated	 under	 vacuum	 to	 yield	 the	
corresponding	 N‐substituted	 derivatives	 (4a‐g)	 the	 crude	
compounds	were	recrystallized	from	hot	aq.	ethanol	to	obtain	
pure	products.	Scheme	1.	
	
2.3.4.	General	procedure	for	the	synthesis	of	Suzuki	
coupling	[24‐26]	compounds	5a‐n	
	
To	a	solution	of	N‐alkylated	benzimidazole	compounds	4a‐
g	 (2.5	 mmol)	 in	 toluene	 (50	 mL)	 was	 added	 phenylboronic	
acid	 and	 4‐ethylphenylboronic	 acid	 (3	 mmol),	 presence	 of	
potassium	 fluoride	 (5	mmol),	 18‐crown‐6	 ether	 (1.25	mmol)	
and	palladium	acetate	(0.125	mmol).	The	reaction	mixture	was	
then	refluxed	and	maintained	 for	3	h	 (TLC	monitored).	Upon	
completion,	 reaction	 mixture	 was	 allowed	 to	 cool	 to	 room	
temperature	 and	 filtered	 through	 hyflo.	 The	 toluene	 filtrate	
was	 washed	 with	 5%	 NaHCO3	 (25	 mL),	 brine	 (25	 mL)	 and	
water	 (25	 L	 and	 dried	 over	 anhydrous	 sodium	 sulphate.	
Evaporation	of	the	solvent	yielded	crude	products,	which	were	
subjected	 to	 column	 chromatography	 to	 isolate	 the	 pure	
products	5a‐n,	Scheme	2.	
	
2.3.5.	Synthesis	of	Suzuki	coupling	compounds	5a‐n	via	
microwave	irradiation	
	
To	a	solution	of	N‐alkylated	benzimidazole	compounds	4a‐
g	 (2.5	 mmol)	 in	 toluene	 (50	 mL)	 was	 added	 phenylboronic	
acid	 and	 4‐ethylphenylboronic	 acid	 (3	 mmol),	 presence	 of	
potassium	 fluoride	 (5	mmol),	 18‐crown‐6	 ether	 (1.25	mmol)	
and	 palladium	 acetate	 (0.125	 mmol)	 was	 heated	 under	
microwave	conditions	at	150	°C	and	200	Watt	for	2	minutes.	It	
was	allowed	to	cool	to	room	temperature	and	filtered	through	
hyflo.	 The	 toluene	 filtrate	was	washed	with	 5%	NaHCO3	 (25	
mL),	 brine	 (25	 mL)	 and	 water	 (25	 mL)	 and	 dried	 over	
anhydrous	 sodium	 sulphate.	 Evaporation	 of	 the	 solvent	
yielded	 crude	 products,	 which	 were	 subjected	 to	 column	
chromatography	to	isolate	the	pure	products	5a‐n,	Scheme	2.	
2‐(Biphenyl‐4‐yloxymethyl)‐1‐methyl‐1H‐benzoimidazole	
(5a):	Colour:	White.	Yield:	60%.	M.p.:	83‐85	°C.	FT‐IR	(KBr,	,	
cm‐1):	2961	(C‐H),	1683	(C=N),	1011	(C‐O).	1H	NMR	(400	MHz,	
CDCl3,	δ,	ppm):	3.80	(s,	3H,	CH3‐N‐),	5.29	(s,	2H,	CH2‐O‐),	6.86‐
6.90	 (d,	 2H,	 J	=	 8.1	Hz,	 Ar‐H),	 7.18‐7.34	 (m,	 8H,	 Ar‐H),	 7.43‐
7.45	(d,	1H,	J	=	8	Hz,	Ar‐H),	7.71‐7.75	(dd,	2H,	J	=	8.7	Hz,	Ar‐H).	
MS	 (EI,	m/z	 (%)):	 315.2	 (M+1).	Anal.	 calcd.	 for	C21H18N2O:	 C,	
80.23;	H,	5.77;	N,	8.91.	Found:	C,	80.10;	H,	5.90;	N,	9.04%.		
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Scheme	2
	
	
2‐(Biphenyl‐4‐yloxymethyl)‐1‐ethyl‐1H‐benzoimidazole	
(5b):	Colour:	White.	Yield:	70.27%.	M.p.:	88‐90	°C.	FT‐IR	(KBr,	
,	 cm‐1):	 2902	 (C‐H),	 1674	 (C=N),	 1045	 (C‐O).	 1H	 NMR	 (400	
MHz,	 CDCl3,	 δ,	 ppm):	1.46‐1.50	 (t,	 J	 =	 7.24	 Hz,	 3H,	 CH3‐CH2),	
4.33‐4.38	(q,	J	=	7.24	Hz,	2H,	CH2‐N),	5.41	(s,	2H,	CH2‐O‐),	7.14‐
7.17	(m,	2H,	Ar‐H),	7.25‐7.33	(m,	3H,	Ar‐H),	7.38‐7.42	(m,	3H,	
Ar‐H),	 7.51‐7.53	 (d,	 J	=	8.84	Hz,	 4H,	Ar‐H),	7.79‐7.81	 (dd,	 J	=	
6.92	Hz,	1H,	Ar‐H).	MS	(EI,	m/z	(%)):	329.2	(M+1).		Anal.	calcd.	
for	 C22H20N2O:	 C,	 80.46;	 H,	 6.14;	 N,	 8.53.	 Found:	 C,	 80.56;	 H,	
6.20;	N,	8.65.	MS	(m/z):	(M+1)	329.2%.	
2‐(Biphenyl‐4‐yloxymethyl)‐1‐propyl‐1H‐benzoimidazole	
(5c):	Colour:	White.	Yield:	64.86%.	M.p.:	95‐98	°C.	FT‐IR	(KBr,	
,	 cm‐1):	 2947	 (C‐H),	 1672	 (C=N),	 1045	 (C‐O).	 1H	 NMR	 (400	
MHz,	 CDCl3,	 δ,	 ppm):	1.02‐1.05	 (t,	 J	 =	 7.40	 Hz,	 3H,	 CH3‐CH2),	
1.90‐2.00	(m,	2H,	CH2‐CH3),	4.27‐4.31	(t,	J	=	7.30	Hz,	2H,	CH2‐
N),	 5.44	 (s,	 2H,	 CH2‐O‐),	 7.17‐7.19	 (d,	 J	=	 8.64	Hz,	 2H,	 Ar‐H),	
7.28‐7.34	(m,	3H,	Ar‐H),	7.40‐7.45	(m,	3H,	Ar‐H),	7.54‐7.56	(d,	
J	=	8.32	Hz,	4H,	Ar‐H),	7.80‐7.84	(dd,	J	=	8.28	Hz,	1H,	Ar‐H).	MS	
(EI,	 m/z	 (%)):	 343.2	 (M+1).	 Anal.	 calcd.	 for	 C23H22N2O:	 C,	
80.67;	H,	6.48;	N,	8.18.	Found:	C,	80.60;	H,	6.60;	N,	8.12%.		
2‐(Biphenyl‐4‐yloxymethyl)‐1‐butyl‐1H‐benzoimidazole	
(5d):	 Colour:	 White.	 Yield:	 68.91%.	 M.p.:	 100‐103	 °C.	 FT‐IR	
(KBr,	,	 cm‐1):	 2961	 (C‐H),	 1683	 (C=N),	 1011	 (C‐O).	 1H	NMR	
(400	MHz,	 CDCl3,	 δ,	 ppm):	0.94‐0.98	 (t,	 J	=	 7.40	 Hz,	 3H,	 CH3‐
CH2)	 ,	1.38‐1.46	(m,	2H,	CH2‐CH3),	1.82‐1.89	(m,	2H,	CH2‐CH2‐
CH3	),	4.27‐4.31	(t,	J	=	7.64	Hz,	2H,	CH2‐N	),	5.42	(s,	2H,	CH2‐O),	
7.13‐7.17	(m,	2H,	Ar‐H),	7.25‐7.33	(m,	3H,	ArH),	7.37‐7.42	(m,	
3H,	Ar‐H),	 7.50‐7.53	 (m,	 4H,	Ar‐H),	 7.79‐7.84	 (dd,	 J	=	6.8	Hz,	
1H,	 Ar‐H).	 MS	 (EI,	 m/z	 (%)):	 357.2	 (M+1).	 Anal.	 calcd.	 for	
C24H24N2O:	C,	80.87;	H,	6.79;	N,	7.86.	Found:	C,	80.70;	H,	6.85;	
N,	7.81%.		
2‐(Biphenyl‐4‐yloxymethyl)‐1‐isobutyl‐1H‐benzoimidazole	
(5e):	 Colour:	 White.	 Yield:	 66.21%.	 M.p.:	 99‐102	 °C.	 FT‐IR	
(KBr,	,	 cm‐1):	 2937	 (C‐H),	 1676	 (C=N),	 1037	 (C‐O).	 1H	NMR	
(400	MHz,	CDCl3,	δ,	ppm):	0.97‐0.99	(d,	J	=	6.68	Hz,	6H,	(CH3)2‐
CH),	2.33‐2.38	(m,	1H,	CH‐CH2),	4.11‐4.13	(d,	 J	=	7.64	Hz,	2H,	
CH2‐N),	5.42	(s,	2H,	CH2‐O),	7.14‐7.16	(d,	J	=	8.72	Hz	2H,	Ar‐H),	
7.25‐7.32	(m,	3H,	Ar‐H),	7.36‐7.42	(m,	3H,	Ar‐H),	7.51‐7.54	(d,	
J	=	8.4	Hz,	4H,	Ar‐H),	7.79‐7.81	(dd,	J	=	6.52	1H,	Ar‐H).	MS	(EI,	
m/z	(%)):	357.2	(M+1).	Anal.	calcd.	for	C24H24N2O:	C,	80.87;	H,	
6.79;	N,	7.86.	Found:	C,	80.70;	H,	6.90;	N,	7.80%.		
1‐Benzyl‐2‐(Biphenyl‐4‐yloxymethyl)‐1H‐benzoimidazole	
(5f):	 Colour:	 White.	 Yield:	 70.27%.	 M.p.:	 158‐161	 °C.	 FT‐IR	
(KBr,	,	 cm‐1):	 2961	 (C‐H),	 1677	 (C=N),	 1011	 (C‐O).	 1H	NMR	
(400	MHz,	CDCl3,	δ,	ppm):	5.39	(s,	2H,	CH2‐O),	5.56	(s,	2H,	CH2‐
N),	7.05‐7.08	(m,	2H,	Ar‐H),	7.10‐7.13	(m,	2H,	Ar‐H),	7.28‐7.31	
(m,	7H,	Ar‐H),	7.41‐7.44	 (m,	2H,	Ar‐H),	7.49‐7.55	 (m,	4H,	Ar‐
H),	7.85‐7.87	(dd,	J	=	7.40,	1H,	Ar‐H).	MS	(EI,	m/z	(%)):	391.2	
(M+1).	 Anal.	 calcd.	 for	 C27H22N2O:	 C,	 80.05;	 H,	 5.68;	 N,	 7.17.	
Found:	C,	79.85;	H,	5.80;	N,	7.12%.		
	
2‐(Biphenyl‐4‐yloxymethyl)‐1‐trifluoromethanesulfonyl‐1H‐
benzoimidazole	 (5g):	 Colour:	 Yellow.	 Yield:	 80%.	M.p.:	 85‐88	
°C.	FT‐IR	(KBr,	,	 cm‐1):	2825	(C‐H),	1621	(C=N),	1352	(S=O),	
1069	(C‐O).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	5.41	(s,	2H,	CH2‐
O),	7.14‐7.17	(m,	2H,	Ar‐H),	7.25‐7.33	(m,	3H,	Ar‐H),	7.38‐7.42	
(m,	 3H,	Ar‐H),	 7.51‐7.53	 (d,	 J	=	8.84	Hz,	 4H,	Ar‐H),	 7.79‐7.81	
(dd,	 J	 =	 6.92	 Hz,	 1H,	 Ar‐H).	 MS	 (EI,	m/z	 (%)):	 433.2	 (M+1).	
Anal.	calcd.	for	C21H15F3N2O3S:	C,	58.33;	H,	3.50;	N,	6.48.	Found:	
C,	58.25;	H,	3.60;	N,	6.42%.	
2‐(4’‐Ethyl‐biphenyl‐4‐yloxymethyl)‐1‐methyl‐1H‐benzoimi	
dazole	 (5h):	Colour:	White.	Yield:	61.04%.	M.p.:	84‐87	°C.	FT‐
IR	(KBr,	,	cm‐1):	2948	(C‐H),	1623	(C=N),	1024	(C‐O).	1H	NMR	
(400	MHz,	 CDCl3,	 δ,	 ppm):	 1.17‐1.21	 (t,	 J	=	7.64	Hz,	 3H,	 CH3‐
CH2),	2.57‐2.63	 (q,	 J	=	7.64	Hz,	2H,	CH2‐CH3),	3.83(s,	3H,	CH3‐
N),	5.35	(s,	2H,	CH2‐O),	7.04‐7.08	(m,	2H,	Ar‐H),	7.15‐7.19	(m,	
2H,	 Ar‐H),	 7.21‐7.31	 (m,	 3H,	 Ar‐H),	 7.36‐7.38	 (m,	 2H,	 Ar‐H),	
7.41‐7.45	(m,	2H,	Ar‐H),	7.69‐7.72	(dd,	J	=	7.12	Hz	 ,1H,	Ar‐H).	
MS	 (EI,	m/z	 (%)):	 343.2	 (M+1).	Anal.	 calcd.	 for	C23H22N2O:	 C,	
80.67;	H,	6.48;	N,	8.18.	Found:	C,	80.52;	H,	6.60;	N,	8.10%.		
2‐(4’‐Ethyl‐biphenyl‐4‐yloxymethyl)‐1‐ethyl‐1H‐benzoimi	
dazole	(5i):	Colour:	White.	Yield:	71.20%.	M.p.:	90‐93	°C.	FT‐IR	
(KBr,	,	 cm‐1):	 2902	 (C‐H),	 1639	 (C=N),	 1043	 (C‐O).	 1H	NMR	
(400	MHz,	CDCl3,	 δ,	ppm):	1.24‐1.28	(t,	 J	=	7.60	Hz,	CH3‐CH2),	
1.47‐1.51	(t,	 J	=	7.2	Hz,	3H,	CH3‐CH2‐N),	2.64‐2.70	(q,	 J	=	7.60	
Hz,	2H,	CH2‐CH3),	4.34‐4.39(q,	J	=	7.2	Hz,	2H,	N‐CH2‐CH3),	5.41	
(s,	2H,	CH2‐O),	7.13‐7.16	(m,	2H,	Ar‐H),	7.23‐7.27	(m,	2H,	Ar‐
H),	7.28‐7.34	(m,	2H,	Ar‐H),	7.37‐7.41	(m,	1H,	Ar‐H),	7.44‐7.46	
(d,	 J	=	8.16	Hz,	 2H,	 Ar‐H),	 7.49‐7.53	 (m,	 2H,	 Ar‐H),	 7.79‐7.81	
(dd,	 J	=	6.96,	1H,	Ar‐H).	MS	(EI,	m/z	(%)):	357.2	(M+1).	Anal.	
calcd.	for	C24H24N2O:	C,	80.87;	H,	6.79;	N,	7.86.	Found:	C,	80.90;	
H,	6.90;	N,	7.82%.		
2‐(4’‐Ethyl‐biphenyl‐4‐yloxymethyl)‐1‐propyl‐1H‐benzoimi	
dazole	(5j):	Colour:	White.	Yield:	60.13%.	M.p.:	85‐89	°C.	FT‐IR	
(KBr,	,	 cm‐1):	 2960	 (C‐H),	 1675	 (C=N),	 1010	 (C‐O).	 1H	NMR	
(400	MHz,	 CDCl3,	 δ,	 ppm):	0.89‐0.93	 (t,	 J	=	 7.64	 Hz,	 3H,	 CH3‐
CH2),	1.17‐1.21	(t,	 J	=	7.6	Hz,	3H,	CH3‐CH2),	1.78‐1.86	 (m,	2H,	
CH2‐CH3),	2.57‐2.63	(q,	J	=	7.64	Hz,	2H,	CH2‐CH3),	4.13‐4.17	(t,	
J=	7.64	Hz,	2H,	CH2‐CH2‐CH3),	5.30	(s,	2H,	CH2‐O),	6.87‐6.90	(m,	
2H,	 Ar	 H),	 7.16‐7.26	 (m,	 5H,	 Ar	 H),	 7.29‐7.33	 (m,	 4H,	 Ar	 H)	
7.75‐7.77	(dd,	J	=	6.64	Hz,	1H,	Ar‐H).	MS	(EI,	m/z	(%)):	371.2	
(M+1).	 Anal.	 calcd.	 for	 C25H26N2O:	 C,	 81.05;	 H,	 7.25;	 N,	 7.56.	
Found:	C,	80.92;	H,	7.25;	N,	7.45%.	
2‐(4’‐Ethyl‐biphenyl‐4‐yloxymethyl)‐1‐butyl‐1H‐benzoimida	
zole	(5k):	Colour:	White.	Yield:	63.22%.	M.p.:	101‐104	°C.	FT‐
IR	(KBr,	,	cm‐1):	2947	(C‐H),	1660	(C=N),	1031	(C‐O).	1H	NMR	
(400	MHz,	 CDCl3,	 δ,	 ppm):	 0.87‐0.89	 (t,	 J	=	7.64	Hz,	 3H,	 CH3‐
CH2),	 1.18‐1.20	(t,	 J	=	7.64	Hz,	3H,	CH3‐(CH2)3),	1.32‐1.34	 (m,	
2H,	CH2‐CH3),	1.78‐1.84	(m,	2H,	CH2‐CH3),	2.57‐2.63	(q,	J	=	7.64	
Hz,	2H,	CH2‐CH2‐CH3),	4.13‐4.17	(t,	 J	=	7.64	Hz,	2H,	CH2‐	CH2‐
CH2‐CH3),	 5.30	 (s,	 2H,	 CH2‐O),	 6.87‐6.90	 (m,	 2H,	 Ar	 H),	 7.16‐
7.26	(m,	5H,	Ar	H),	7.29‐7.33	(m,	4H,	Ar	H),	7.75‐7.77	(dd,	J	=	
6.64	Hz,	1H,	Ar	H).			
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Table	1.	Antibacterial	activity	of	compound	5a‐n	(Minimal	inhibition	concentration,	MIC).		
Compound	 Antibacterial	activity	(MIC,	µg/mL)	
E.	coli	 P.	Aeruginosa S.	Aureus S.	Pyogenus	
5a	 100	 62.5	 200	 100	
5b	 125	 100	 62.5	 200	
5c	 100	 100 200 250	
5d	 62.5 100 125 250	
5e	 125	 200 125 100	
5f	 250	 100 250 125	
5g	 100	 200 100 125	
5h	 100	 100 250 250	
5i	 250	 200	 250	 250	
5j	 250	 125	 100	 250	
5k	 100	 125	 125	 200	
5l	 200	 250 250 500	
5m	 150	 200	 250	 250	
5n	 125	 250 250 100	
Gentamycin	 0.05	 1	 0.25	 0.5	
Ampicillin	 100	 ‐	 250	 100	
Chloramphenicol	 50	 50	 50	 50	
Ciprofloxacin	 25	 25 50 50	
Norfloxacin	 10	 10	 10	 10	
	
	
Table	2.	Antifungal	activity	of	compound	5a‐n	(Minimal	inhibition	concentration,	MIC).	
Compound	 	 Antifungal	activity	(MIC,	µg/mL)
C.	Albicans	 A.	Niger	 A.	Clavatus	
5a	 250 >1000 >1000
5b	 >1000	 500	 500	
5c	 500	 500	 500	
5d	 >1000	 >1000 >1000
5e	 1000	 250	 500	
5f	 500	 >1000	 >1000	
5g	 1000	 1000 1000
5h	 250	 500 500
5i	 1000	 250 250
5j	 500	 500 500
5k	 1000	 500 1000
5l	 >1000	 >1000 >1000
5m	 >1000	 >1000 >1000
5n	 500	 500	 500	
Nystatin	 100	 100 100
Greseofulvin	 500	 100 100
	
	
MS	 (EI,	m/z	 (%)):	 385.2	 (M+1).	Anal.	 calcd.	 for	C26H28N2O:	 C,	
81.25;	H,	7.34;	N,	7.29.	Found:	C,	81.35;	H,	7.50;	N,	7.25%.		
2‐(4’‐Ethyl‐biphenyl‐4‐yloxymethyl)‐1‐isobutyl‐1H‐benzoimi	
dazole	(5l):	Colour:	White.	Yield:	61.77%.	M.p.:	103‐105	°C.	FT‐
IR	(KBr,	,	cm‐1):	2960	(C‐H),	1683	(C=N),	1011	(C‐O).	1H	NMR	
(400	MHz,	CDCl3,	δ,	ppm):	0.95‐0.99	(d,	J	=	6.68	Hz,	6H,	(CH3)2‐
CH2),	1.24‐1.28	(t,	J	=	7.64	Hz,	3H,	CH3‐CH2)	2.33‐2.40	(m,	1H,	
CH‐(CH3)2,	2.65‐2.70	(q,	J	=	7.6	Hz,	2H,	CH2‐CH3),	4.11‐4.13	(d,	J	
=	7.6	Hz,	2H,	 ‐N‐CH2),	 5.41	 (s,	 2H,	 ‐O‐CH2),	 7.12‐7.15	 (m,	 2H,	
Ar‐H),	7.23‐7.32	(m,	4H,	Ar‐H),	7.36‐7.39	(m,	1H,	Ar‐H),	7.44‐
7.44	(d,	 J	=	8.16	Hz,	2H,	Ar‐H),	7.49‐7.53	(m,	2H,	Ar‐H),	7.78‐
7.80	(dd,	J	=	6.64	Hz,	1H,	Ar‐H).	MS	(EI,	m/z	(%)):	385.3	(M	+1).	
Anal.	calcd.	for	C26H28N2O:	C,	81.25;	H,	7.34;	N,	7.29.	Found:	C,	
81.15;	H,	7.50;	N,	7.24%.		
1‐Benzyl‐2‐(4’‐ethyl‐biphenyl‐4‐yloxymethyl)‐1H‐benzoimi	
dazole	 (5m):	 Colour:	White.	 Yield:	 62.50%.	M.p.:	 160‐164	 °C.	
FT‐IR	 (KBr,	,	 cm‐1):	 2963	 (C‐H),	1693	 (C=N),	1008	 (C‐O).	 1H	
NMR	 (400	 MHz,	 CDCl3,	 δ,	 ppm):	1.17‐1.20	 (t,	 J	 =	 7.6	 Hz,	 3H,	
CH3‐CH2),	2.57‐2.63	(q,	J	=	7.52	Hz,	2H,	‐CH2‐CH3),	5.46	(s,	2H,	‐
O‐CH2),	5.56	(s,	2H,	‐N‐CH2),	6.93‐6.96	(m,	2H,	Ar‐H),	7.00‐7.02	
(m,	2H,	Ar‐H),	7.17‐7.24	 (m,	8H,	Ar‐H),	7.35‐7.41	 (m,	4H,	Ar‐
H),	 7.74‐7.76	 (dd,	 J	 =	 7.12	 Hz,	 2H,	 Ar‐H).	 MS	 (EI,	m/z	 (%)):	
319.3	 (M	+1).	Anal.	 calcd.	 for	C29H26N2O:	C,	 83.22;	H,	6.26;	N,	
6.69.	Found:	C,	83.32;	H,	7.41;	N,	6.60%.		
2‐(4’‐ethyl‐biphenyl‐4‐yloxymethyl)‐1‐trifluoromethane	
sulfonyl‐1H‐benzoimidazole	 (5n):	 Colour:	 Yellow.	 Yield:	
75.63%.	M.p.:	80‐83	°C.	FT‐IR	(KBr,	,	cm‐1):	2945	(C‐H),	1656	
(C=N),	 1348	 (S=O),	 1026	 (C‐O).	 1H	 NMR	 (400	MHz,	 CDCl3,	 δ,	
ppm):	1.24‐1.28	(t,	J	=	7.60	Hz,	3H,	CH3‐CH2),	2.64‐2.70	(q,	J	=	
7.60	Hz,	2H,	CH2‐CH3),	5.41	(s,	2H,	 ‐O‐CH2),	7.13‐7.16	(m,	2H,	
Ar‐H),	7.23‐7.27	(m,	2H,	Ar‐H),	7.28‐7.34	(m,	2H,	Ar‐H),	7.37‐
7.41	(m,	1H,	Ar‐H),	7.44‐7.46	(d,	 J	=	8.16	Hz,	2H,	Ar‐H),	7.49‐
7.53	 (m,	 2H,	Ar‐H),	 7.79‐7.81	 (dd,	 J	 =	6.96	Hz,	 1H,	Ar‐H).	MS	
(EI,	m/z	(%)):	461.07	(M	+1).	Anal.	calcd.	for	C23H19F3N2O3S:	C,	
59.99;	H,	4.16;	N,	6.08.	Found:	C,	60.05;	H,	4.25;	N,	6.02%.		
	
2.4.	Biological	evaluation‐antibacterial	and	antifungal	
activity	studies	
	
The	 microbial	 activity	 was	 undertaken	 to	 evaluate	 the	
effect	of	the	synthesized	compounds	on	different	bacteria	and	
fungal	 strains.	 The	 compounds	5a‐n	were	 screened	 for	 their	
antibacterial	 activity	 [27,28]	against	human	pathogenic	Gram	
negative	 bacteria	 such	 as	 Escherichia	 coli	 MTCC442,	
Pseudomonas	aeruginosa	MTCC441	and	Gram	positive	bacteria	
Staphylococcus	 aureus	 MTCC96,	 and	 Streptococcus	 pyogenes	
MTCC443.	 DMSO	 was	 used	 as	 diluents	 and	 Gentamycin,	
Ampicillin,	Chloramphenicol,	Ciprofloxacin	and	Norfloxacin	as	
standard.	 The	 compounds	5a‐n	 were	 also	 screened	 for	 their	
antifungal	 activity	 [29]	 against	 Candida	 albicans	 MTCC227,	
Aspergillus	 Niger	 MTCC282	 and	 Aspergillus	 clavatus	
MTCC1323.	 Broth	 dilution	method	 was	 used	 to	 evaluate	 the	
antibacterial	activity.	It	is	carried	out	in	tubes.	Mueller	Hinton	
Broth	[30]	was	used	as	nutrient	medium.	Serial	dilutions	were	
prepared	 in	 primary	 and	 secondary	 screening.	 Each	
synthesized	 drug	 was	 diluted	 obtaining	 2000	 μg/mL	
concentration,	as	a	stock	solution.	In	primary	screening	1000,	
500	 and	 250	 μg/mL	 concentrations	 of	 the	 synthesized	 drugs	
were	taken.	The	drugs	found	active	in	primary	screening	were	
similarly	 diluted	 to	 obtain	 200,	 100,	 50,	 25,	 12.5,	 and	 6.250	
μg/mL,	 and	 concentrations.	 The	 highest	 dilution	 showing	 at	
least	99%	inhibition	zone	was	taken	as	MIC.	
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3.	Results	and	discussion		
	
We	 have	 synthesized	 a	 series	 of	 novel	 benzimidazoles;	
initially	we	have	carried	out	 the	condensation	of	o‐phenylene	
diamine	(OPDA)	(1)	with	4‐bromophenoxy	acetic	acid	(2)	in	4	
N	HCl	at	reflux	temperature	for	6	h.	After	simple	workup	gives	
2‐(4‐bromo‐phenoxymethyl)‐1H‐benzimidaziole	 (3)	 [22]	
(Scheme	1).		
Having	 obtained	 compound	 3,	 we	 have	 carried	 out	 N‐
alkylation	to	get	compounds	4a‐g	(Scheme	1).	Compounds	4a‐
g	were	 then	 reacted	 phenyl	 boronic	 acid	 and	 4‐ethylphenyl	
boronic	 acid	 in	 presence	 of	 potassium	 fluoride,	 palladium	
acetate	and	18‐crown‐6	under	suzuki	coupling	condition	to	get	
compounds	 N‐substituted	 2‐(biphenyl‐4‐yloxymethyl)‐1H‐
benzimidazole,	 2‐(4’‐ethyl‐biphenyl‐4‐yloxymethyl)‐1H‐benzi‐
midazole	 derivatives	 (5a‐n)	 (Scheme	 2).	 It	 is	 noteworthy	 to	
mention	here	that	we	have	synthesized	compound	3	and	5a‐n	
alternatively	 by	 microwave	 irradiation	 in	 comparable	 yield,	
which	 give	 the	 scope	 of	 alternative	 route	 to	 synthesis	
benzimidazoles	at	 low	temperature	and	 in	 less	reaction	 time.	
The	 structures	 of	 all	 the	 synthesized	 compounds	 were	
characterized	 by	 spectroscopic	 data,	 and	 allowed	 these	
molecules	for	study	of	antibacterial	and	antifungal	activities.	
The	 examination	 of	 the	 data	 reveals	 that	 compounds	5a,	
5c,	5d,	5g,	5h	and	5k	possess	high	activity	against	Escherichia	
coli	 whereas	 compounds	 5a‐n	 were	 highly	 active	 against	
Staphylococcus	aureus	and	compound	5a,	5e,	and	5n	have	also	
exerted	 very	 good	 activity	 against	 Streptococcus	 pyogenes	
employed	 for	 screening,	 the	 results	are	presented	 in	Table	1.	
The	 compounds	 5a	 and	 5h	 show	 excellent	 activity	 against	
Candida	 albicans.	 But	 rests	 of	 other	 compounds	 are	 not	
displayed	 significant	 anti‐fungal	 activity	 when	 compared	 to	
the	 standard	 Nystatin	 and	 Greseofulvin;	 the	 results	 are	
presented	in	Table	2.	
	
4.	Conclusion	
	
Newly	 synthesized	 N‐substituted	 2‐(biphenyl‐4‐yloxy	
methyl)‐1H‐benzimidazole,	 2‐(4’‐ethyl‐biphenyl‐4‐yloxymeth	
yl)‐1H‐benzimidazole	 derivatives	 by	 using	 Suzuki	 coupling	
conditions	were	 thoroughly	 characterized	 and	 some	 of	 them	
exhibited	 antibacterial	 activity.	 The	 compounds	 5a	 and	 5h	
exhibited	 antifungal	 activity.	 However,	 antifungal	 activity	 of	
the	other	synthesized	compounds	was	unsatisfactory.	
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